With up to 95% of small molecules failing to transition from Discovery through to Clinic, the selection of the right candidate is an essential step to increase the chances of success. Understanding potential pitfalls in the following areas are key to selecting the right candidate.
This webinar will describe how the One Step approach of coordinated activities from Discovery through to Clinical Development (Drug Product and Drug Substance) ensures risks are mitigated early. We will show how establishing a clear CMC strategy during early Lead Optimization, including development chemistry, ensured the right studies were performed to support rapid progress into clinical enabling studies via a seamless, and comprehensive Technology Transfer into a trusted CDMO.
Establishing a target product profile (TTP), risk profile and determining developability early in the process derisks the lead optimization stages by improving the chances of selecting the best overall lead candidate molecule.
It’s a fact that very few large project plans survive intact once the data starts coming through. Having a single point of contact actively coordinating all ongoing activities greatly simplifies project management efforts, keeps costs down, and results in the best scientific outcomes. Clients have an accessible and knowledgeable advocate, from bench to bedside.
One CRO partner and one point of contact simplifies project management efforts, keeps costs down, and results in the best scientific outcomes. Clients have an accessible and knowledgeable advocate, from bench to bedside.
Register today to discover how to improve chances of clinical success.
RegisterKey Learning Objectives
- Building a strategy to drive hit identification through to pre-clinical candidate identification
- Seamlessly managing the integration of discovery and development activities
- Derisking the lead optimization stages and therefore improving the chances of the best lead candidate selection
- Creating bespoke solutions for partners illustrated through case studies
